Fortress Biotech, Inc. FBIOP Cash Flow

Fortress biotech, inc. (FBIOP)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Cash Flows from Operating Activities:
Net loss
-109,473	-101,660	-108,120	-111,737	-119,973	-141,936	-128,539	-136,259	-123,492	-99,836	-95,120	-75,769	-69,209	-71,290	-65,063	-67,962	-57,991	-53,883	-42,521	-27,258	-25,551	-20,386	0	0	0	-	-	-	-
Net loss on discontinued operations
-	-	-	-	-	-13,469	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from continuing operations
-	-	-	-	-	-130,800	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24	26	0	0	0	-	-	-	-	-	-	-	-
Stock-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Noncash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	167	246	246	307	634	0	0	0	-	-	-	-
Change in fair value of Common Stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Change in fair value of embedded conversion feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Change in fair value of Preferred Stock warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Depreciation expense
1,946	1,900	1,914	1,838	1,685	1,400	807	683	648	726	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Amortization expense of intangible asset
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount
3,446	3,321	3,059	2,693	2,380	2,419	3,644	3,686	3,556	3,141	2,196	1,745	1,343	1,466	757	653	683	314	0	0	0	-	-	-	-	-	-	-	-
Non cash interest expense
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of product revenue license fee
1,295	1,174	1,053	846	767	666	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets
1,580	1,558	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of product revenue license fee
-	-	-	-	-	-	-	-	-	-	-	429	316	183	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of forgivable loans to registered representatives
-	-	-	-	-	-	-	-	-	-	696	538	377	176	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred clearing credit
-	-	-	-	-	-	-	-	-	-	-170	-117	-65	-13	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
13,279	13,188	13,382	13,747	13,526	15,012	13,408	13,614	15,269	13,403	15,384	13,975	12,191	12,128	11,187	16,785	15,687	14,291	13,360	6,343	5,881	5,546	0	0	0	-	-	-	-
Common shares issuable for Opus interest expense
155	281	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of subsidiaries' common shares for research and development expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-493	-	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of subsidiaries' assets and liabilities
-	-	-	-	-	-	-	-	-	104	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of subsidiaries' assets and liabilities
-	-	-	-	-	-	-	-	-	104	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issuable for 2017 Subordinated Note Financing interest expense
522	500	500	496	490	495	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Recovery of doubtful accounts
-	-	-	-	-	-	-	-	-	-	321	303	162	47	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Noncash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Noncash interest expense-related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Contribution of services by stockholder
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Common shares issuable for 2017 Subordinated Note financing interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Common shares issued for 2017 Subordinated Note financing interest expense
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing fees on subsidiaries' Convertible Note, at fair value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of investments
-	-	-	-	-	-1,390	-923	-88	776	226	488	137	-821	-1,071	-3,410	-4,801	-2,378	-1,675	1,170	2,349	727	942	0	0	0	-	-	-	-
Change in fair value of derivative liability
0	-	-	-	705	682	5,409	6,060	4,687	368	-4,221	-4,844	-3,392	1,039	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Change in fair value of partner company convertible note
-	-	-	-	-	437	-72	-62	-110	-457	-424	-363	-175	-78	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of partner company convertible note
-	-	-	-	-	437	-72	-62	-110	-457	-424	-363	-175	-78	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Gain on deconsolidation of Caelum
-92	-18,476	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development-licenses acquired, expense
5,800	6,000	1,320	4,326	4,127	3,774	4,574	1,167	2,996	4,164	4,089	4,790	5,068	3,838	4,626	4,920	4,512	11,406	0	0	0	-	-	-	-	-	-	-	-
Asset impairment loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	722	723	723	723	0	0	0	0
Unrealized (gain) loss on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Realized gain on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Accounts receivable
7,888	8,141	-44	-1,967	-292	-2,260	-151	1,985	6,946	5,928	5,464	2,369	1,368	1,830	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Receivables from broker-dealers and clearing organizations
-	-	-	-	-	-	-	-	-	-	8,973	3,504	3,549	4,048	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Forgivable loans receivable
-	-	-	-	-	-	-	-	-	-	161	131	101	84	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Securities owned, at fair value
-	-	-	-	-	-	-	-	-	-	-583	1,228	-972	179	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
140	179	267	433	407	507	356	0	18	-32	195	199	204	203	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other receivables - related party
-376	-1,230	829	1,075	1,185	1,477	-224	-830	-90	-1,172	-907	-965	-280	1,634	1,476	2,528	1,314	156	0	0	0	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
1,078	-1,798	-3,237	-4,083	-3,946	3	4,013	2,161	6,112	4,011	833	2,989	-597	204	1,211	291	927	739	418	501	90	124	262	143	195	117	0	0	0
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-
Other assets
128	882	1,120	635	623	17	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current assets held for sale
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Noncurrent assets held for sale
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current liabilities held for sale
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
6,371	2,095	1,252	-5,402	-5,173	4,686	6,049	13,814	18,728	10,651	4,226	103	3,344	5,395	6,878	8,540	4,205	5,889	4,892	1,557	1,592	-849	-434	-1,314	951	1,184	0	0	0
Accounts payable and accrued expenses - related party
-295	-149	0	0	0	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses - related party
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Securities sold, but not yet purchased, at fair value
-	-	-	-	-	-	-	-	-	-	0	77	1	298	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest payable
-52	8	1,196	649	921	917	-120	429	191	176	42	65	63	61	42	0	1	-1	1	1	1	-81	-91	-91	-94	-10	0	0	0
Interest payable - related party
34	-5	-577	-572	-560	-572	169	340	560	602	496	325	96	66	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Lease liabilities
-1,068	-1,365	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
End of term fee associated with Hercules Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-398	-398	-398	-398	0	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-
Other long-term liabilities
-186	749	1,045	1,065	1,341	472	226	-38	-261	-284	110	1,226	2,510	4,346	4,830	3,941	2,527	195	-1,226	-1,038	-964	-464	0	0	0	-	-	-	-
Net cash used in continuing operating activities
-	-	-	-	-	-97,063	0	0	0	-	-	-	-	-	-	0	-30,110	-	-16,843	-14,319	-12,165	-16,334	-19,939	-24,440	-28,228	-29,646	0	0	0
Net cash used in discontinued operating activities
-	-	-	-	-	-1,785	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-91,528	-94,961	-92,069	-100,567	-96,329	-98,848	-97,549	-97,872	-97,674	-81,305	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows from Investing Activities:
Payment to related parties - CB Pharma Acquisition Corp
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-
Deposit for leasehold improvements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Purchase of research and development licenses
-	-	-	-	-	1,074	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Purchase of long-term investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,925	0	0	0	-	-	-	-
Purchase of research and development licenses
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	3,554	-	0	0	0	-	-	-	-	-	-	-	-
Purchase of property and equipment
2,571	2,345	1,794	3,424	6,617	7,082	6,392	4,807	1,152	648	1,613	2,524	4,338	6,370	5,945	4,534	2,576	283	0	0	0	-	-	-	-	40	0	0	0
Security deposits refund
-	-	-	-	-	-	-	-	-	42	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Security deposits refund
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of business - National
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of intangible assets
0	-	-	-	0	-	-	-	-	-	-	-	-	350	350	350	200	1,250	1,250	1,250	1,250	0	0	0	0	-	-	-	-
Purchase of short-term investment (certificates of deposit)
-	-	-	-	-	52,604	59,541	71,053	81,091	56,091	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of short-term investment (certificates of deposit)
10,044	22,604	27,604	52,604	59,562	71,002	81,091	56,091	44,089	20,089	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deconsolidation of Caelum
0	-1,201	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of business - National
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Collection on notes receivable
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in Origo Acquisition Corp.
-	-	-	-	-	-	-	-	-	-	-	-	-	175	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by (used in) continuing investing activities
-5,827	7,008	10,437	23,518	21,940	9,041	0	0	0	-	-	-	-	-	-	0	13,469	-	-54,013	-32,764	-31,310	-23,273	-596	-467	-436	-188	0	0	0
Net cash provided by discontinued investing activities
0	13,089	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) investing activities
-5,827	20,097	33,309	46,390	44,812	18,824	11,079	-23,088	-41,122	-40,224	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows from Financing Activities:
Payment of Preferred A dividends
3,180	2,559	2,359	2,344	2,344	2,344	2,057	1,471	885	299	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of treasury stock
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of costs related to purchase of treasury stock
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of Series A preferred stock
0	-	-	-	-1,144	154	26,297	26,297	26,298	25,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from PCP notes payable-related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of PCP notes payable-related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of PCP notes payable?TSO asset purchase
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of notes payable-related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,502	1,314	47,703	80,128	91,337	0	0	0
Proceeds from notes payable-related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from issuance of Convertible Preferred Stock Series
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of costs related to the issuance of Series A preferred stock
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32	70	937	1,930	1,898	0	0	0
Proceeds from at-the-market offering
20,497	20,680	16,414	17,324	13,296	7,274	6,959	4,070	229	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of cost related to at-the-market offering
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of cost related to issuance of common stock for at-the-market offering
-	-	-	-	-	257	240	141	6	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of Hercules Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-1	-1	13,654	0	0	0	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	27	0	0	0	-	-	-	-	216	812	812	812	596	0	0	0	-	-	-	-
Proceeds from partner company's ESPP
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from partner company's sale of stock
51,181	86,180	66,623	66,623	34,999	23,011	14,094	24,275	62,224	95,117	132,044	132,945	94,996	39,662	56,894	58,387	58,387	57,817	0	0	0	-	-	-	-	-	-	-	-
Payment of costs related to partner company's sale of stock
3,240	6,671	4,754	5,386	1,676	343	-9,046	-508	-831	0	0	0	0	-	-	0	0	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from partner company's at-the-market offering
35,157	30,526	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of costs related to partner company's at-the-market offering
817	741	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Assumption of PCP Note related to Asphelia Asset Purchase
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from exercise of partner company's warrants
0	-	-	-	85	181	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs associated with 2017 Subordinated Note Financing
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from 2017 Subordinated Note Financing
-	-	-	-	-	-	-	-	-	28,355	28,355	18,967	3,254	0	0	0	0	10,000	10,000	10,000	10,000	0	0	0	0	-	-	-	-
Payment of costs related to the issuance of Common Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Cashless Exercise Of Warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of debt issuance costs associated with 2017 Subordinated Note Financing
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	855	855	855	855	0	0	0	0	-	-	-	0
Proceeds from IDB Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14,009	14,009	14,009	14,009	0	0	0	0
Proceeds from Opus Credit Facility
-	-	-	-	-	-	-	-	-	2,500	4,500	9,500	9,000	7,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from 2018 Venture Notes
-	-	-	-	-	21,707	21,707	21,707	21,707	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs associated with 2018 Venture Notes
74	134	126	120	121	1,868	1,868	1,863	1,814	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of NSC Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	9	9	9	9	0	0	0	0
Proceeds from borrowings under line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Proceeds from partner company's Horizon Notes
0	15,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Payment of debt issuance costs associated with partner company's Horizon Notes
1,163	1,393	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of partner company's Convertible Notes
-	-	-	-	-	4,408	4,076	4,076	1,858	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs associated with IDB Note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Transfer of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by continuing financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	49,128	-	24,827	12,322	12,421	-10,155	-14,140	32,819	64,594	89,156	0	0	0
Net cash provided by financing activities
117,354	146,714	117,867	122,271	63,106	50,648	72,998	80,181	131,876	150,381	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash and cash equivalents, cash deposits with clearing organizations and restricted cash
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	32,487	-	-46,029	-34,761	-31,054	-49,762	-34,675	7,912	35,930	59,322	0	0	0
Net (decrease) increase in cash and cash equivalents and restricted cash
19,999	71,850	59,107	68,094	11,589	-29,376	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information:
Cash paid for interest
5,953	5,444	4,657	5,167	5,154	4,448	3,963	2,018	597	207	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest - related party
-	-	-	-	-	281	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	77	-	251	251	331	785	949	1,303	1,574	1,387	0	0	0
Supplemental disclosure of non-cash financing and investing activities:
Settlement of restricted stock units into common stock
2	2	3	3	4	3	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of restricted stock
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	2	-	1	1	1	4	0	0	0	-	-	-	0
Receivable from ATM issuances
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of warrants by subsidiary in conjunction with NSC debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of partner companies'' common shares for settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of warrants in conjunction with 2017 Subordinated Note Financing
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt discount related to Opus Credit Facility
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Debt discount related to Opus Credit Facility
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid debt offering costs
0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issuable for license acquired
0	164	0	0	0	-	-	-	-	1,682	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issued for 2017 Subordinated Note Financing interest expense
0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of partner company warrants in conjunction with Horizon Notes
0	888	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid fixed assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid at-the-market offering cost
0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid Preferred A offering cost
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unpaid research and development licenses acquired
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issued for 2017 Subordinated Note Financing interest expense
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property, plant and equipment included in account payable and accrued liabilities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fixed assets acquired but not paid
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inter-company costs related to the issuance of Series A preferred stock
0	-	-	-	-1,144	154	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Business acquisition
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-